streetAsia s premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. SUBSCRIBE NOW
Singapore Reporter/s
In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digi
Edna Ruth Thompson began her journey of life in Bradley County, on June 23, 1931. Her journey ended on Thursday, June 3, 2021, when she met her Heavenly Father.
Share:
COPENHAGEN, Denmark, 18 May 2021 /PRNewswire/ Novo Holdings today announced that it has led the oversubscribed US$125 million Series C financing in Hummingbird Bioscience (Hummingbird), an innovative clinical-stage biotech company focused on developing precision therapies against difficult-to-drug targets to improve treatment outcomes. This is one of the first investments in a privately-held Asian biotech company by Novo Holdings. Novo Holdings recently established an Asian life sciences investment platform in Singapore, Novo Holdings Equity Asia Pte. Ltd. ( Novo Holdings Asia ). Kenneth Harrison, Partner, Novo Ventures, will join Hummingbird s board of directors.
Hummingbird, headquartered in Singapore and the US, is developing a broad pipeline of first- and best-in-class drug candidates across multiple indications for the treatment of cancer. Proceeds from the financing will be used to advance the clinical development of Hummingbird s lead assets including HMBD-001,
SG biotech startup Hummingbird Bioscience bags $125m Series C funding
Antibody visual sourced from Hummingbird s website
May 18, 2021
Singapore-based biotech startup Hummingbird Bioscience has announced raising $125 million in a Series C funding round led by life science investor Novo Holdings.
A syndicate of international biotech investors also participated in the funding round, including Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital, and others.
The biotech startup, which raised $25 million in an extended Series B round in May 2020, said it will use the fresh funding to advance the clinical development of its lead assets, including the antibody HMBD-001, which targets HER3, a cell surface protein associated with several cancers, including colorectal, gastric, and lung.